Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

BACKGROUND: Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors. METHODS: Phase 1 evaluated the safety of varlilumab (0.1–10 mg/kg) with nivolumab (3 mg/kg) administered once every 2 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanborn, Rachel E, Pishvaian, Michael J, Callahan, Margaret K, Weise, Amy, Sikic, Branimir I, Rahma, Osama, Cho, Daniel C, Rizvi, Naiyer A, Sznol, Mario, Lutzky, Jose, Bauman, Julie E, Bitting, Rhonda L, Starodub, Alexander, Jimeno, Antonio, Reardon, David A, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim M, Subramaniam, Deepa S, Aragon-Ching, Jeanny B, Hawthorne, Thomas R, Rawls, Tracey, Yellin, Michael, Keler, Tibor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364417/
https://www.ncbi.nlm.nih.gov/pubmed/35940825
http://dx.doi.org/10.1136/jitc-2022-005147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364417/
https://www.ncbi.nlm.nih.gov/pubmed/35940825
http://dx.doi.org/10.1136/jitc-2022-005147

Ejemplares similares